Login to Your Account

Gilead Sciences shares dip on concern over HCV drug sales

By Michael Fitzhugh
Staff Writer

Wednesday, October 28, 2015

Despite posting an estimate-beating 70 percent rise in third quarter net profit, slowing sales growth for Gilead Sciences Inc.'s HCV drugs attributed to payer restrictions weighed on company shares on Wednesday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription